Dr. Hiren Patel is a Professor in the Department of Electrical and Computer Engineering at the University of Waterloo. He holds a Doctorate in Computer Engineering from Virginia Tech and previously worked as a postdoctoral fellow at UC Berkeley under Edward A. Lee. His research focuses on real-time embedded systems, computer architecture, machine learning hardware, and cybersecurity. He teaches courses like ECE 150 (Programming), ECE 320/429 (Computer Architecture), and ECE 327 (Digital Systems). Research Interests: Cyber-physical systems and hybrid architectures Hardware/software co-design methodologies Predictable cache coherence protocols IoT and edge computing systems Security in embedded and real-time systems Recent work emphasizes cache coherence solutions for safety-critical systems and GPU acceleration strategies. His publications address challenges in multicore predictability, FPGA bandwidth optimization, and autonomous robotics orchestration. No specific awards are listed, though his extensive publication record indicates significant contributions to embedded systems research. He currently oversees graduate student applications focusing on his core research areas.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Carme Torras Genís is a Research Professor at the Spanish National Research Council (CSIC), affiliated with the Institute of Robotics and Industrial Informatics (IRI) in Barcelona and the Technical University of Catalonia (UPC). Her career spans over three decades, focusing on robotics, neurocomputing, and artificial intelligence with applications in healthcare and deformable object manipulation. M.Sc. in Mathematics (University of Barcelona, 1978) M.Sc. in Computer Science (University of Massachusetts, 11981) Ph.D. in Computer Science (UPC, 1984) Research Interests : Robotic manipulation of deformable objects (especially textiles) Neurocomputing and machine learning for robotic control Human-robot interaction and assistive robotics Computational topology for cloth state representation Ethics in social robotics and AI Medical applications of robotics for neuromuscular disease assessment Scientific Leadership : ERC Advanced Grant recipient (2016) IEEE and EurAI Fellow Coordinator of Horizon Europe project SoftEnable and former ERC project CLOTHILDE Editorial leadership in IEEE Transactions on Robotics and multiple journals Active in ethics committees and AI policy advisory boards Advisory Committee of Ethics in AI (Catalan Government) Vice-President of CSIC Ethics Committee Member of Royal Academy of Engineering (Spain)
Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.
Foteini Mourkioti is an Associate Professor at the University of Pennsylvania's Perelman School of Medicine , with a joint appointment in the Graduate Groups of Cell and Molecular Biology and Bioengineering . She co-directs the Musculoskeletal Regeneration Program at the Penn Institute of Regenerative Medicine and leads the McKay Orthopaedic Research Laboratory . Research Interests : Muscle Stem Cell Biology Mechanobiology Muscle Regeneration Telomere Biology in Muscular Diseases Fibrodysplasia Ossificans Progressiva (FOP) Cardiomyopathy and Aging Key Research Contributions : Developed the Pax7EGFP mouse model for real-time muscle stem cell tracking Discovered telomere shortening as a critical factor in Duchenne Muscular Dystrophy Elucidated the role of NF-κB in muscle stem cell dysfunction Identified Piezo1's role in stem cell morphological states Characterized fibro-adipogenic progenitor dynamics in FOP Scientific Awards : NIH/NHLBI R01 grant recipient (2019) NASA grant awardee (2020, 2017) American Heart Association grant (2017) Muscular Dystrophy Association grant (2019) University Research Foundation grant (2018) Publications & Collaborations : Over 25 publications in high-impact journals like Science Advances , Nature Protocols , and Cell Reports . Collaborates with Penn Cardiovascular Institute and Pennsylvania Muscle Institute.
Dr. Ian Wilson is a researcher at Newcastle University with a focus on medical genetics, nephrology, and genomic analysis. His work spans genetic determinants of kidney diseases, mitochondrial disorders, and biomarker development. Notable contributions include studies on uromodulin genetics in African populations, copy-number variations in rare diseases, and kidney ciliopathies. He has collaborated extensively on projects involving genome sequencing, mitochondrial replacement therapy, and muscular dystrophy biomarkers. Wilson's research integrates computational tools like machine learning for predictive modeling in urolithiasis and employs advanced imaging techniques for disease progression monitoring. Key areas: Genetic epidemiology, renal genomics, mitochondrial DNA analysis Focus on translational applications: Biomarker development for kidney stones and muscular dystrophies Interdisciplinary collaborations in ophthalmology and orthopedics His publications reflect a commitment to advancing diagnostic accuracy and understanding complex genetic disorders through multi-omics approaches.
Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.
Pablo Perez-Pinera is an Associate Professor in Biomedical and Translational Sciences at the Carle Illinois College of Medicine, University of Illinois. He leads the Genome Engineering and Transcriptional Regulation Laboratory, focusing on developing gene editing technologies for treating neurodegenerative and neuromuscular diseases. His research integrates cutting-edge genome engineering tools with innovative delivery systems to address previously incurable conditions. Dr. Perez-Pinera's research interests center on developing CRISPR-based genome editing technologies for therapeutic applications. His laboratory specializes in base editing approaches for exon skipping, particularly targeting diseases like Duchenne muscular dystrophy, Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS. His team develops novel delivery systems using AAV vectors to enable precise in vivo genome editing, with a particular focus on neurological and muscular disorders. The lab's work bridges fundamental molecular biology with translational applications, aiming to move promising technologies from bench to bedside. His laboratory has made significant contributions to the field of therapeutic genome editing, particularly in developing the SPLICER platform for efficient exon skipping through simultaneous splice site editing. His publications demonstrate expertise in base editing for neurodegenerative diseases, with multiple first-author and corresponding author papers in high-impact journals. His research has been supported by several NIH grants including R01 GM131272, UL1 TR001422, R01 GM141296, among others. Dr. Perez-Pinera actively mentors a diverse team of researchers including postdoctoral fellows, graduate students, and undergraduates. His laboratory includes researchers such as Devyani Swami (Postdoctoral Fellow), Michael Gapinske, Jackson Winter, Shraddha Shirguppe, Angelo Miskalis, and others who contribute to various aspects of genome engineering research. His grant funding supports both basic research on genome editing mechanisms and translational work toward therapeutic applications. The Genome Engineering and Transcriptional Regulation Laboratory maintains state-of-the-art facilities for molecular biology, cell culture, and in vivo studies. The team collaborates extensively with clinicians and researchers across the University of Illinois campus to translate genome editing discoveries into potential therapies for patients suffering from neurodegenerative and neuromuscular conditions.
Prof. Casper Hoogenraad is a full professor in Molecular Neuroscience at the Department of Cell Biology, Faculty of Science, Utrecht University. His research focuses on understanding how intracellular protein trafficking underlies neuronal development and function, with particular emphasis on the microtubule cytoskeleton, synaptic cargo trafficking, and synaptic plasticity. He leads an active research group within Utrecht University's Cell Biology department and collaborates extensively with other neuroscience research groups. Education: PhD, Erasmus University Rotterdam (1996-2001) Postdoc, Massachusetts Institute of Technology (2002-2005) Hoogenraad's research spans three main themes: cytoskeleton dynamics during neurodevelopment and synaptic plasticity, motor proteins and adaptors as regulators of synaptic transport, and psychiatric and neurologic disease disorders linked to intracellular transport. His work combines genetics, biochemistry, molecular, and cellular biology methods in in vitro (neuron cultures), ex vivo (brain slices), and in vivo (mice) systems, along with advanced microscopy techniques including immunofluorescent confocal microscopy, high-resolution live cell imaging, and photo-activated localization microscopy (PALM). Analysis of Hoogenraad's recent publications reveals a strong focus on microtubule organization, neuronal polarity, and the molecular mechanisms underlying synaptic function and dysfunction. His work frequently explores how disruptions in intracellular transport contribute to neurological disorders including Alzheimer's disease, schizophrenia, and autism spectrum disorders, with particular attention to the relationship between cytoskeletal organization and cargo transport in neuronal compartments. Scientific Awards and Memberships: ZonMW-VIDI (2004) European Young Investigators (EURYI) award (2005) NWO-ALW VICI (2011) ERC Consolidator grants (2013) FENS-Kavli Network of Excellence (2014) European Molecular Biology Organization (EMBO) (2015) Young Academy of Europe (YAE) (2015) IBRO Kemali Prize (2016) Hoogenraad leads a research group studying neuronal development and function, with a particular focus on how intracellular transport mechanisms contribute to both normal brain function and neurological disorders. His laboratory employs a multidisciplinary approach combining molecular, cellular, and systems neuroscience techniques to investigate the molecular basis of neuronal polarity, synaptic plasticity, and the pathogenesis of neurological disorders. He has secured significant research funding through prestigious grants including ERC Consolidator grants. The Hoogenraad lab operates within the Cell Biology department at Utrecht University, collaborating with other research groups focusing on cellular dynamics, biophysics, and neurobiology. The lab utilizes advanced microscopy techniques including immunofluorescent confocal microscopy, high-resolution live cell imaging (spinning disc microscopy and total internal reflection fluorescence microscopy), and quantitative analysis using advanced high-resolution microscopy (photo-activated localization microscopy). Current lab technicians include Phebe Wulf and Bart de Haan.
Zhi-Pei Liang is the Franklin W. Woeltge Professor in the Department of Electrical and Computer Engineering at the University of Illinois at Urbana-Champaign, with joint appointments in the Department of Bioengineering, Beckman Institute for Advanced Science and Technology, and Coordinated Science Laboratory. His research spans biomedical engineering, medical imaging, and signal processing with a focus on advancing magnetic resonance imaging and spectroscopy technologies. His educational background includes a Ph.D. in Biomedical Engineering from Case Western Reserve University (1989) and a B.S. in Electrical Engineering from South-China University of Technology (1982), followed by postdoctoral training at UIUC (1989-1991). Professor Liang's research interests center on magnetic resonance imaging and spectroscopy , with particular emphasis on ultrafast imaging techniques , model-based reconstruction methods , and the integration of physics-based modeling with machine learning . His pioneering work on SPICE (SPectroscopic Imaging by exploiting spatiospectral CorrElation) has revolutionized high-resolution metabolic brain imaging by enabling label-free molecular imaging through the marriage of spin physics and machine learning. His research spans pattern recognition, parameter estimation, image formation theory, and algorithms for medical imaging applications. Analysis of his recent publications reveals a strong focus on high-resolution metabolic imaging , particularly using SPICE methodology to map brain metabolism with unprecedented detail. His work bridges fundamental physics of magnetic resonance with advanced computational methods to overcome traditional limitations in imaging speed and resolution. Current research directions include J-resolved spectroscopic imaging, deuterium-based metabolic mapping, and multimodal integration of PET and MRSI for studying neurological disorders. Elected to International Academy of Medical and Biological Engineering (2012) Gold Medal, International Society for Magnetic Resonance in Medicine (2022) Technical Achievement Award, IEEE Engineering in Medicine and Biology Society (2014) Fellow, National Academy of Inventors (2021) Author of influential book 'Principles of Magnetic Resonance Imaging' (1999) President of IEEE Engineering in Medicine and Biology Society (2011-2012) Professor Liang has advised numerous students and postdocs in biomedical imaging research and has received multiple teaching honors including the Ronald W. Pratt Outstanding Teaching Award (2005) and multiple listings among UIUC's Excellent Teachers. His research has been supported by various grants from NIH, NSF, and other funding agencies. He leads the SPICE (Spectroscopic Imaging by exploiting spatiospectral Correlation) research group which focuses on developing novel imaging techniques that combine physics-based modeling with machine learning for ultrafast metabolic imaging. His laboratory, part of the Beckman Institute's Integrative Imaging Theme, collaborates extensively with clinical researchers at Carle Illinois College of Medicine and other institutions to translate advanced imaging techniques into clinical applications for neurological disorders, cancer, and metabolic diseases. Current projects focus on high-resolution mapping of brain metabolism in Alzheimer's disease, stroke, and brain tumors using novel MR spectroscopic imaging techniques.
Johanna Pirker serves as an Associate Professor at the Institute of Human-Centred Computing, Graz University of Technology, where she holds teaching authorization in Applied Computer Science. Her work bridges academic research with practical applications in interactive technologies, maintaining active consultation hours for students every Monday morning. Her research centers on human-centered computing with emphases on virtual/augmented reality systems, serious game design, and AI-driven interactive experiences. She investigates player behavior, user experience optimization, and therapeutic/educational applications of immersive technologies across diverse contexts including rehabilitation, engineering education, and social platforms. Recent 2025 publications reveal strong trends in AI integration for gaming ecosystems (toxicity detection, dialogue systems), VR-based educational tools across disciplines, and cross-cultural analyses of gaming communities. Her work consistently combines experimental user studies with novel system development to address real-world challenges. While specific grant details and student advising records aren't documented in source materials, her extensive publication output across venues like FDG and iLRN indicates active leadership in interdisciplinary collaborations focused on advancing immersive technologies for societal benefit.
Bernard Brais serves as Director of the Rare Neurological Diseases Group at the Montreal Neurological Institute-Hospital (The Neuro), which operates as a McGill University research and teaching institute and is part of the Neuroscience Mission of the McGill University Health Centre. His academic appointment at McGill University positions him within one of Canada's premier neuroscience research environments. Dr. Brais completed his MDCM, neurology residency, and PhD at McGill University, establishing his deep institutional connections. He additionally possesses specialized training as a historian of neurosciences and genetics, which informs his comprehensive approach to neurological disorders. His research program centers on the genetic basis of neurogenetic disorders with founder effects in Quebec populations, with particular emphasis on disorders exhibiting ataxic manifestations such as Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS). Since 2007, he has led a dedicated research team investigating ARSACS, building on his earlier work identifying causal genes for Oculopharyngeal muscular dystrophy (OPMD), Hereditary Sensory and Autonomic Neuropathy type II (HSANII), Limb Girdle Muscular Dystrophy with Quadriceps atrophy (LGMD2L), Pol III-related leukodystrophies, and ZAK congenital myopathy. Analysis of Dr. Brais's publication record reveals a cohesive research trajectory spanning clinical studies of disease progression, molecular genetics investigations of causal mutations, and preclinical work with animal models. His work consistently focuses on rare neurological conditions with strong genetic components, particularly those showing founder effects in Quebec populations, with substantial contributions to understanding neuromuscular disorders, ataxias, leukodystrophies, and neuropathies. As Director of the Rare Neurological Diseases research group, Dr. Brais oversees multiple research initiatives investigating various rare neurological conditions. His laboratory work integrates clinical research with basic science approaches, utilizing patient populations for clinical studies while employing cellular and animal models to elucidate disease mechanisms. His clinical work is associated with the Neuromuscular Programme at The Neuro, where he applies his research findings to patient care.
Shushu Huang is an Associate Research Scientist in the Department of Genetics at Yale School of Medicine. They hold a PhD from Nanjing Medical University (2023) and an MD from the same institution (2013). Their research focuses on genetic and molecular mechanisms underlying metabolic disorders, muscular dystrophies, and cardiovascular diseases. Key areas include CRISPR-based therapeutic discovery, high-throughput functional genomics, and gene therapy safety. Huang has collaborated with researchers like Monkol Lek and Carlos Fernandez-Hernando on projects involving LXR signaling, DUX4 toxicity, and MC4R variant analysis. Publications span studies on vascular biology, gene therapy outcomes, and obesity genetics. Notable work includes investigating hypercholesterolemia’s role in vascular remodeling and analyzing MC4R variants in morbid obesity. Their lab is located in the Anlyan Center, New Haven.
Dr. Elliot L. Dimberg is a neurologist specializing in neuromuscular disorders at Mayo Clinic Hospital in Jacksonville, Florida. He serves as faculty at Mayo Clinic Alix School of Medicine within the Department of Neurology, holding leadership roles including Vice Chair of the Curriculum Committee and Clerkship Sub Committee. Dr. Dimberg actively contributes to medical education through multiple committees related to student promotions, academic affairs, and residency program evaluation, while maintaining a clinical practice focused on complex neuromuscular conditions. Dr. Dimberg earned his MD from Tulane University in 2001. He completed his Neurology residency and served as Chief Resident at the University of Virginia, followed by fellowships in Clinical Neurophysiology at the University of Virginia (2006) and Neuromuscular Disease at Mayo Clinic Rochester (2008). He maintains board certification in Neurology, Clinical Neurophysiology, and Neuromuscular Medicine through the American Board of Psychiatry and Neurology. His clinical expertise spans neuromuscular junction disorders including myasthenia gravis and Lambert-Eaton Myasthenic Syndrome, peripheral neuropathies, brachial and lumbosacral plexus disorders, polyradiculopathies, motor neuron diseases, and myopathies. Dr. Dimberg integrates clinical evaluation with electrodiagnostic medicine to diagnose and manage these complex conditions. His research focuses on advancing diagnostic methodologies through electromyography techniques, genetic testing, and clinical trial participation for rare neuromuscular disorders. Dr. Dimberg's publication record demonstrates consistent contributions to neuromuscular medicine, with emphasis on diagnostic precision, genetic underpinnings of muscle disorders, and therapeutic innovations. His recent work includes clinical trials for hereditary transthyretin amyloidosis, studies on spinal muscular atrophy treatments, and investigations into immune-mediated necrotizing myopathy, reflecting his commitment to advancing both clinical practice and scientific understanding in his field. Multiple Above and Beyond Awards from Mayo Clinic in Florida (2008-2024) A.B. Baker Teacher Recognition Award from American Academy of Neurology (2013, 2021) Commitment to Education Award from Mayo Clinic Alix School of Medicine (2019) Alpha Omega Alpha Honor Society membership (2000) As an educator, Dr. Dimberg has coordinated the Residency Neuroanatomy Course and Clinical Pathological Correlation Conference for over a decade. He previously chaired the Curriculum Committee for the Adult Neurology Residency Program and currently serves in leadership roles for Mayo Clinic Alix School of Medicine's educational committees. His dedication to teaching has been recognized through numerous awards including the prestigious A.B. Baker Teacher Recognition Award. Professionally, Dr. Dimberg serves as Co-Chair of the American Association of Neuromuscular and Electrodiagnostic Medicine's EDX Lab Accreditation Committee and holds leadership positions in the American Clinical Neurophysiology Society. He contributes to developing certification exams, educational programming, and clinical guidelines for these organizations, maintaining active engagement with the broader neuromuscular medicine community.
Megan Laura McCain is a Professor of Biomedical Engineering at the University of Southern California (USC), with a secondary appointment in the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine. She leads the McCain Lab, focused on developing microphysiological systems, particularly heart- and muscle-on-a-chip models, to study disease mechanisms and therapeutic responses. McCain holds affiliations with the Biomedical Engineering Society, American Society for Cell Biology, and American Heart Association. Her education includes a B.S. in Biomedical Engineering from Washington University in St. Louis (2006), a Ph.D. in Engineering and Applied Sciences from Harvard University (2012), and postdoctoral research at Harvard’s Wyss Institute. Notable awards include the American Heart Association Pre-doctoral Fellowship and Harvard’s Derek Bok Certificate of Distinction in Teaching. McCain’s research integrates tissue engineering, stem cell biology, and microfluidics to model complex biological systems. Her work emphasizes understanding how microenvironments influence cellular behavior in diseases like cardiovascular disorders and muscular dystrophy. Recent studies explore paracrine interactions in engineered tissues, sex-based proteomic differences in vascular cells, and hypoxia-induced signaling in cardiac fibroblasts. Her scientific contributions include advancements in 3D bioprinting, microfluidic platforms for disease modeling, and synthetic biology tools for cellular control. McCain’s lab collaborates widely to translate findings into clinical applications, such as personalized medicine and regenerative therapies.
